AstraZeneca looks to combos after effective ex-Ardea drug shows serious adverse effects

AstraZeneca's top-line gout data released 13 December shows efficacy for lesinurad but also a worrying range of serious adverse events. While the Phase III LIGHT study was designed to test lesinurad's utility in patients who cannot tolerate some standard-of-care and commonly used gout drugs, lesinurad's adverse event profile might threaten its regulatory or market success. Now the company will look to the drug's performance in combinations with standard gout treatments.